U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H14ClN3O4S3
Molecular Weight 431.937
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BENZTHIAZIDE

SMILES

NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC3=CC=CC=C3)NS2(=O)=O

InChI

InChIKey=NDTSRXAMMQDVSW-UHFFFAOYSA-N
InChI=1S/C15H14ClN3O4S3/c16-11-6-12-14(7-13(11)25(17,20)21)26(22,23)19-15(18-12)9-24-8-10-4-2-1-3-5-10/h1-7H,8-9H2,(H,18,19)(H2,17,20,21)

HIDE SMILES / InChI

Molecular Formula C15H14ClN3O4S3
Molecular Weight 431.937
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Benzthiazide (trade names Aquatag, Dihydrex, Diucen, Edemax, Exna, Foven and others) is a thiazide diuretic used in the treatment of high blood pressure and edema. It is no longer available in the United States. As a diuretic, benzthiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. The following is a list of possible side effects that may occur from all constituting ingredients of Exna Tablet: vomiting, diarrhoea, photosensitivity reactions, increased in uric acid concentrations, megaloblastic anaemia, thrombocytopenia. Exna tablet may interact with the following drugs and products: ACE inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.0167 µM [Kd]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
EXNA
Primary
EXNA

T1/2

ValueDoseCo-administeredAnalytePopulation
10 h
unknown, oral
BENZTHIAZIDE unknown
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
90%
unknown, oral
BENZTHIAZIDE unknown
Homo sapiens

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​

PubMed

Sample Use Guides

In Vivo Use Guide
Hypertension: 50-100 mg/day; maintenance: individualize dose (maximum effective dose: 200 mg/day)
Route of Administration: Oral
In Vitro Use Guide
Carbon dioxide protects the carbonic anhydrase from inhibition by benzthiazide. After equilibration of inhibitor with enzyme in the presence of substrate, an inhibition is observed at a drug concentration 100-fold higher than that required for a similar inhibition after equilibration in the absence of substrate.
Substance Class Chemical
Record UNII
1TD8J48L61
Record Status Validated (UNII)
Record Version